The global apheresis market, valued at US$ 2.9 Billion in 2023, is projected to reach US$ 6.7 Billion by 2034, growing at a CAGR of 7.7% during the forecast period. Apheresis, a specialized medical procedure, involves extracting specific blood components—red blood cells, white blood cells, platelets, and plasma—for therapeutic and diagnostic purposes. This process, facilitated by a centrifuge, separates blood components and isolates the targeted elements, returning the remaining components to the bloodstream. Apheresis is widely employed in treating blood disorders, autoimmune diseases, and certain cancers, making it a crucial aspect of the healthcare industry.
The Significance of Apheresis:
Apheresis has become increasingly valuable in both clinical and research settings due to its versatility and tailored treatment capabilities. Its applications are expanding, driven by advancements in technology, leading to more precise and efficient procedures. Automated apheresis devices, for instance, have streamlined the process, improving patient comfort and reducing separation time. Emerging technologies like selective adsorption and microfluidics offer more accurate extraction of specific blood components, further enhancing the efficacy of apheresis.
Regional Insights: Asia Pacific Dominance:
The Asia Pacific region dominated the apheresis market in 2023 and is expected to maintain its leadership throughout the forecast period. The rising incidence of blood-related disorders, such as leukemia, thalassemia, and immune-mediated hematologic conditions, is a key driver. Additionally, innovations in apheresis devices, increased government investments in healthcare infrastructure, the establishment of blood banks and treatment centers, and growing awareness of the benefits of therapeutic apheresis among healthcare professionals and patients are contributing to the region’s market dominance.
Key Players Shaping the Market:
Several leading players are actively shaping the global apheresis market, including:
* Terumo Corporation
* Fresenius Kabi AG
* B. Braun SE
* NIKKISO Co., Ltd.
* Medica SPA.
* Asahi Kasei Medical Co. Ltd.
* Haemonetics Corporation
* Cerus Corporation
* Kawasumi Laboratories America
* Therakos, Inc.
Recent Developments in the Apheresis Industry:
In February 2024, the National Institute of Health and Care Research invested £1.5M in 25 red blood cell exchange devices for patients with sickle cell disease across England. This investment, allocated to 22 NHS trusts, aims to improve patient care by providing access to these devices in hospitals. With approximately 15,000 people in England living with sickle cell disease, this initiative has the potential to increase apheresis procedures by 10,000 annually, further highlighting the growing importance of apheresis in treating specific conditions.
The apheresis market is evolving rapidly, propelled by technological advancements and expanding therapeutic applications. Its potential to address a wide range of medical needs makes it a significant player in the future of healthcare.
